Mars Bleu, a campaign to raise awareness about colorectal cancer screening
You may have heard about Pink October, a month dedicated to breast cancer awareness and screening. If you didn’t know it yet, there is also the national colorectal cancer awareness month; it’s March and it’s called Mars Bleu (Blue March).
Colorectal cancer is the second most deadly cancer in the world, while early detection increases the chances of survival. More than 90% of patients diagnosed at an early stage can be definitively cured.
Thus, Mars Bleu is the month dedicated to raising awareness for screening and prevention of colorectal cancer in many countries. Each year, Mars Bleu is a great opportunity to raise awareness for the prevention and screening of colorectal cancer. This is an opportunity to remind people that a colorectal cancer detected early can save lives: the earlier a colorectal cancer is detected, the easier it is treated.
Mars Bleu is also an opportunity to convey the following message: colonoscopy, stool test or blood test – whatever the method you choose, the most important is to get screened AND get your loved ones screened.
Novigenix engages in Mars Bleu by launching a communication campaign for the prevention and screening of colorectal cancer which can be discovered on www.mymiddlelife.ch.
About Colox®:
Colox® is a proven molecular blood test that has been designed to support physicians in case
finding of patients with CRC and adenomas for referral to colonoscopy. The test can support
the healthcare community to significantly reduce mortality from colorectal cancer through
early detection and intervention. Colox can be ordered by any physician in routine medical
practice to identify patients with adenomatous polyps and colorectal cancer.
About Novigenix SA:
Novigenix SA is an innovative Swiss molecular diagnostics company focused on the
commercialization of new blood tests for the early detection of cancer. Novigenix’s products
rely on a new generation of predictive molecular signatures and state-of-the-art mathematical
analytical models to provide new solutions for the early detection of cancer. For more
information please visit www.novigenix.com
